Best Practices for Employers to Maximize Uptake of Biosimilars

Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

EP: 2.The Economic Impact of Biosimilars

Now Viewing

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

Video content above is prompted by the following:

• What are best practices for employers working with pharmacy benefit managers and health plans to ensure maximal uptake and cost savings of biosimilars?
• Please share how you were able to achieve this in practice.

Related Videos

Related Content

Advertisement

February 10th 2025

Pain Linked to Greater Cigarette, E-Cigarette, Cannabis Use Among Cancer Survivors

Brooke McCormick

These new data highlight the need for improved pain management among patients with cancer and survivors.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 7th 2025

Keratinocyte Skin Cancer Surgery Considered Safe, Effective in Older Patients

Hayden E. Klein

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 7th 2025

Phase 3 Data Support Nipocalimab for Myasthenia Gravis

Maggie L. Shaw

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and efficacy of nipocalimab for myasthenia gravis.

February 6th 2025

Study Reveals Gaps in Migraine Diagnosis, Treatment for Black and Hispanic Children

Giuliana Grossi

Non-Hispanic Black and Hispanic/Latino children were also significantly less likely to receive brain MRI scans compared with their non-Hispanic White peers.

Related Content

Advertisement

February 10th 2025

Pain Linked to Greater Cigarette, E-Cigarette, Cannabis Use Among Cancer Survivors

Brooke McCormick

These new data highlight the need for improved pain management among patients with cancer and survivors.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 7th 2025

Keratinocyte Skin Cancer Surgery Considered Safe, Effective in Older Patients

Hayden E. Klein

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 7th 2025

Phase 3 Data Support Nipocalimab for Myasthenia Gravis

Maggie L. Shaw

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and efficacy of nipocalimab for myasthenia gravis.

February 6th 2025

Study Reveals Gaps in Migraine Diagnosis, Treatment for Black and Hispanic Children

Giuliana Grossi

Non-Hispanic Black and Hispanic/Latino children were also significantly less likely to receive brain MRI scans compared with their non-Hispanic White peers.